Dr Nina (Ekaterini) Kotsopoulou is the CTO at AAVantgarde Bio. Previously she was CTO at Xap Therapeutics. Prior to Xap she oversaw the development and manufacture of cellular gene therapies, from preclinical to commercial, at GSK, Autolus and Orchard Therapeutics. During that time she played an instrumental role in the approval of Strimvelis and Libmeldy in Europe. She began her career in industry at GSK in biopharmaceuticals. Prior to joining GSK she was a post-doctoral fellow at Harvard Medical School and Cambridge University, focussing on haematopoietic stem cell biology. Nina holds a PhD in lentiviral vectors from Oxford University and a BSc in Chemistry from the University of Athens.